『6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice』のカバーアート

6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice

6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice

無料で聴く

ポッドキャストの詳細を見る

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue rates and fewer central nervous system adverse effects than other androgen pathway inhibitors, while exploring considerations for patient selection, trial design interpretation, and the evolving role of real-world evidence in clinical decision-making.
まだレビューはありません